Hooman  Hakami net worth and biography

Hooman Hakami Biography and Net Worth

EVP of Medtronic
Hooman has 30 years of business leadership experience.  He has worked at two of the largest companies in the world — Medtronic and GE — and was a Corporate Officer of both.  A global executive, he has lived in the UK and France.  During his career he has built a for driving growth, particularly in challenging areas, by executing disruptive and transformational new technologies and through business model innovation.

Hooman is currently advising CEOs & Boards, with an emphasis in Medical Technology.

Relevant Experience
Hooman currently serves on the board of two private companies.  Mpirik is a SaaS company which uses AI and big data to identify high-risk Cardiovascular patients who are in need of more specialized care or surgery.  PathMaker Neurosystems is the only multi-site, non-invasive neuromodulation company that is focused on the treatment of spasticity and the suppression of ALS symptoms.

Previously, Hooman was an Executive Vice President and Group President for Medtronic, with P&L responsibility for the ~$2.5B Diabetes Group.  The Group has 6,000 employees based in locations around the world.  The business unit is a market leader in the field, is a DTC business & is accretive to the overall company growth rate.  During his tenure, Hooman re-focused the Diabetes business, launched a transformational new product and drove market share to record levels.  As a result, the Diabetes Group created $0.7B of incremental, organic growth for Medtronic, growing from $1.8B to approximately $2.5B in just six years.  In addition, Hooman drove a more global presence by expanding manufacturing into new geographies and built the most comprehensive technology pipeline in the Group’s history, with a heavy emphasis on Data Science and AI.Prior to Medtronic, Hooman was the President of GE’s Detection & Guidance Solutions business.  This $2B business comprised of 7 business units with 1,700 employees and 13 manufacturing facilities.  During his tenure, Hooman drove market share, growth & expanded the company’s footprint internationally.  

Personal
Hooman is married to Christine.  They have been married for 25 years and have three children, Hannah, Cameron and Casey.  He enjoys exercise, traveling and spending time with his family. 

What is Hooman Hakami's net worth?

The estimated net worth of Hooman Hakami is at least $2.59 million as of September 10th, 2019. Mr. Hakami owns 30,761 shares of Medtronic stock worth more than $2,587,308 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Hakami may own. Learn More about Hooman Hakami's net worth.

How do I contact Hooman Hakami?

The corporate mailing address for Mr. Hakami and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Hooman Hakami's contact information.

Has Hooman Hakami been buying or selling shares of Medtronic?

Hooman Hakami has not been actively trading shares of Medtronic within the last three months. Most recently, Hooman Hakami sold 82,877 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $107.31, for a transaction totalling $8,893,530.87. Following the completion of the sale, the executive vice president now directly owns 30,761 shares of the company's stock, valued at $3,300,962.91. Learn More on Hooman Hakami's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 4 times. They sold a total of 55,659 shares worth more than $4,695,766.41. The most recent insider tranaction occured on June, 7th when CEO Geoffrey Martha sold 19,113 shares worth more than $1,601,096.01. Insiders at Medtronic own 0.2% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 6/7/2024.

Hooman Hakami Insider Trading History at Medtronic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/10/2019Sell82,877$107.31$8,893,530.8730,761View SEC Filing Icon  
6/12/2019Sell52,664$97.49$5,134,213.3695,337View SEC Filing Icon  
8/31/2018Sell26,159$96.29$2,518,850.1163,046View SEC Filing Icon  
1/5/2018Sell26,158$85.00$2,223,430.00View SEC Filing Icon  
3/2/2017Sell52,316$82.33$4,307,176.2873,800View SEC Filing Icon  
See Full Table

Hooman Hakami Buying and Selling Activity at Medtronic

This chart shows Hooman Hakami's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $84.74
Low: $83.92
High: $85.13

50 Day Range

MA: $89.17
Low: $84.11
High: $92.27

2 Week Range

Now: $84.74
Low: $75.96
High: $92.68

Volume

5,563,154 shs

Average Volume

6,271,332 shs

Market Capitalization

$108.68 billion

P/E Ratio

25.91

Dividend Yield

3.29%

Beta

0.84